PEPTIDE-TRANSPORT ACROSS THE BLOOD-BRAIN-BARRIER

被引：2
作者：
VANBREE, JBMM
DEBOER, AG
VERHOEF, J
DANHOF, M
BREIMER, DD
机构：
[1] Center for Bio-Pharmaceutical Sciences, Division of Pharmacology, University of Leiden, P.O. Box 9503
来源：
JOURNAL OF CONTROLLED RELEASE | 1990年 / 13卷 / 2-3期
关键词：
blood-brain barrier; in vitro; in vivo experimental techniques; peptide transport;
D O I：
10.1016/0168-3659(90)90008-H
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The progress in isolation and culturing techniques of cerebrovascular endothelial cells, which will be briefly reviewed, enabled the development of in vitro models of the blood-brain barrier. The in vitro models, which are by now extensively characterized and validated, can generally be applied to specific aspects of blood-brain barrier anatomy and physiology and can also offer a valuable tool in drug disposition studies. Application of the in vitro model to the specific question of peptide transport across the blood-brain barrier, offers numerous methodological advantages: basic physiological parameters can be controlled and different experimental setups, not available in the in vivo setup, can be applied, thereby offering means to obtain a more thorough understanding of the basic aspects and mechanisms responsible for peptide transport across the blood-brain barrier. This approach will be illustrated by means of studies performed on a vasopressin-like model-peptide and will be presented in perspective of in vivo studies performed with the same peptide. Potential application of the in vitro blood-brain barrier model also includes the field of transport enhancement of poorly transported drugs, a maybe essential prerequisite for further development of peptides into therapeutically beneficial drugs. © 1990.
引用
收藏
页码：175 / 184
页数：10
相关论文
共 71 条
  • [41] Houghten, Swann, Li, β-Endorphin: stability, clearance behaviour and entry into the central nervous system after intravenous injection of the tritiated peptide in rats and rabbits, Proc. Natl. Acad. Sci. U.S.A., 77, pp. 4588-4591, (1980)
  • [42] Ang, Jenkins, Blood-cerebrospinal fluid barrier to arginine-vasopressin, desmopressin and desglycinamide arginine-vasopressin in the dog, J. Endocrinol., 93, pp. 319-325, (1982)
  • [43] Deyo, Shoemaker, Ettenberg, Bloom, Koob, Subcutaneous administration of behaviorally effective doses of arginine vasopressin change AVP brain content only in median eminence, Neuroendocrinology, 42, pp. 260-266, (1986)
  • [44] Zhu, Greeley, Lewis, Lilja, Thompson, Blood-CSF barrier to CCK and effect of centrally administered bombesin on release of brain CCK, J. Neurosci. Res., 15, pp. 393-403, (1986)
  • [45] Levin, Frank, Weber, Ismail, Mills, Studies on the penetration of the blood-brain barrier by atrial natriuretic factor, Biochem. Biophys. Res. Commun., 147, pp. 1226-1231, (1987)
  • [46] Hersh, McKelvy, Enzymes involved in the degradation of thyrotropin releasing hormone and luteinizing hormone releasing hormone in bovine brain, Brain Res., 168, pp. 553-564, (1979)
  • [47] Hersh, McKelvy, An aminopeptidase from bovine brain which catalyses the hydrolysis of enkephalin, J. Neurochem., 36, pp. 171-178, (1981)
  • [48] Griffiths, Kelly, Mechanisms of inactivation of hypothalamic regulatory hormones, Mol. Cell. Endocrinol., 14, pp. 3-17, (1979)
  • [49] Verhoef, Scholtens, Vergeer, Witter, Des-tyr-gamma-endorphin (DTyE) and des-enkephalin-gamma-endorphin (DEyE): plasma profile and brain uptake after systemic administration in the rat, Peptides, 6, pp. 467-474, (1985)
  • [50] Riekkinnen, Legros, Sennef, Jolkkonen, Smitz, Soininen, Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects, Peptides, 8, pp. 261-265, (1987)
12345678